Bispecific ANXA2/CD147 CAR-T cell therapy for osteosarcoma
A novel bispecific ANXA2/CD147 CAR-T cell was developed to provide an experimental basis for improving the therapeutic outcome of osteosarcoma and generated a bispecific ANXA2/CD147 CAR-T cell with robust antitumor activity, providing a promising new strategy for the immunotherapy of osteosarcoma.